Incyclix Bio
  • About Us
    • Mission/Vision
    • Founding Story
    • Leadership
    • Board of Directors
    • Investors
  • Science
    • Approach
    • CDK2 Program
    • Clinical Trials
    • Publications
  • News
    • Press Releases
    • Publications
  • Join Us
  • Contact Us

Publications


INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers

Alec G. Trub1, John E. Bisi1, Catherine Dietrich2, Michael Taylor, Jay C. Strum1, Shom Goel2, Patrick J. Roberts1
1Incyclix Bio, Durham, NC, United States, 2The Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

See the Publication >

Incyclix Bio

600 Park Offices Dr., Suite 355
Research Triangle Park, NC 27709

(919) 328-0003
info@incyclixbio.com

LinkedIn
Twitter

© 2023 Incyclix Bio, Inc. All Rights Reserved.